Translator Disclaimer
1 October 2011 Preliminary Evaluation of Raboral V-RG® Oral Rabies Vaccine in Arctic Foxes (Vulpes lagopus)
Author Affiliations +
Abstract

We tested the Raboral V-RG® recombinant oral rabies vaccine for its response in Arctic foxes (Vulpes lagopus), the reservoir of rabies virus in the circumpolar North. The vaccine, which is currently the only licensed oral rabies vaccine in the United States, induced a strong antibody response and protected foxes against a challenge of 500,000 mouse intracerebral lethal dose 50% of an Arctic rabies virus variant. However, one unvaccinated control fox survived challenge with rabies virus, either indicating a high resistance of Arctic foxes to rabies infection or a previous exposure that induced immunity. This preliminary study suggested that Raboral V-RG vaccine may be efficacious in Arctic foxes.

Erich Follmann, Don Ritter, Rhonda Swor, Mike Dunbar, and Karsten Hueffer "Preliminary Evaluation of Raboral V-RG® Oral Rabies Vaccine in Arctic Foxes (Vulpes lagopus)," Journal of Wildlife Diseases 47(4), 1032-1035, (1 October 2011). https://doi.org/10.7589/0090-3558-47.4.1032
Received: 1 February 2011; Accepted: 1 July 2011; Published: 1 October 2011
JOURNAL ARTICLE
4 PAGES


SHARE
ARTICLE IMPACT
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top